Source Articles
Sintilimab
Showing 3 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feng et al. | 2025 | Prospective | Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study. | 10.1111/1759-7714.70043 | NCT04167657 | 14 | 67 | 40.1 | Lung cancer | — | Anti-PD-(L)1 mAb | Sintilimab | — | — | extra-cranial | lung | 6.0 | 30 | — | — | 5 | — | — | 6 | — | — | Treatment-rel. | — | — | 3 | any G3: 3 AE | any G3: 3 pt |
any G3: immune-related myocarditis, thrombocytopenia, checkpoint inhibitor pneumonitis
|
—
|
| Chen et al. | 2023 | Prospective | Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial | 10.3748/wjg.v29.i24.3871 | NCT0385781 | 25 | 64 | 21.9 | HCC | oligometastatic | Anti-PD-(L)1 mAb | Sintilimab | — | 32 | Missing | Missing | — | 54 | 48.0 | 60.0 | 6 | 6.0 | 10.0 | Missing | Missing | Missing | Treatment-rel. | — | — | 3 | any G3: 3 AEs | any G3: 3 pts |
any G3: increased gGT, decreased platelet count, myositis
|
unknown
|
| Zhou et al. | 2023 | Prospective | Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients | 10.1158/1078-0432.Ccr-23-0315 | NCT03812549 | 29 | 65 | 15.6 | Lung cancer | primary | Anti-PD-(L)1 mAb | Sintilimab | — | Missing | extra-cranial | lung | — | 30 | 30.0 | 30.0 | 3 | 3.0 | 3.0 | 10 | 10 | 10 | Treatment-rel. | — | — | 6 | any G3-4: 6 AEs | any G3-4: 6 pts |
any G3-4: dermatitis, pneumonitis, hypertriglyceridemia, lipase increased, anaphylaxis, hypoadrenocorticism
|
unknown
|